Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124132283 | 12413228 | 3 | F | 201604 | 20160915 | 20160527 | 20160923 | EXP | FR-009507513-1605FRA011514 | MERCK | 77.75 | YR | F | Y | 0.00000 | 20160923 | CN | CH | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124132283 | 12413228 | 1 | PS | DAPTOMYCIN. | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | 1000 MG, BIW (EVERY TWO WEEKS) | Y | 21572 | INJECTION | BIW | |||||||
| 124132283 | 12413228 | 2 | SS | DAPTOMYCIN. | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | 1000 MG, QD | Y | 21572 | 1000 | MG | INJECTION | QD | |||||
| 124132283 | 12413228 | 3 | SS | RIFADIN | RIFAMPIN | 1 | Intravenous (not otherwise specified) | 600 MG, (4 CAPSULES, DAILY FOR TWO DAYS), BID | Y | 0 | 600 | MG | CAPSULE | BID | |||||
| 124132283 | 12413228 | 4 | SS | METRONIDAZOLE. | METRONIDAZOLE | 1 | Intravenous (not otherwise specified) | 500 MG, TID | Y | 0 | 500 | MG | TID | ||||||
| 124132283 | 12413228 | 5 | SS | AZACTAM | AZTREONAM | 1 | Intravenous (not otherwise specified) | 1000 MG, ONCE/SINGLE | Y | 0 | 1000 | MG | 1X | ||||||
| 124132283 | 12413228 | 6 | SS | AZACTAM | AZTREONAM | 1 | Intravenous (not otherwise specified) | 500 MG, TID | Y | 0 | 500 | MG | TID | ||||||
| 124132283 | 12413228 | 7 | SS | PRAVASTATIN. | PRAVASTATIN | 1 | Oral | 20 MG, QD | Y | N | 0 | 20 | MG | QD | |||||
| 124132283 | 12413228 | 8 | SS | PRAVASTATIN. | PRAVASTATIN | 1 | Oral | UNK | Y | N | 0 | ||||||||
| 124132283 | 12413228 | 9 | SS | ESCITALOPRAM OXALATE. | ESCITALOPRAM OXALATE | 1 | Oral | 10 MG, QD | Y | N | 0 | 10 | MG | QD | |||||
| 124132283 | 12413228 | 10 | SS | ESCITALOPRAM OXALATE. | ESCITALOPRAM OXALATE | 1 | Oral | UNK | Y | N | 0 | ||||||||
| 124132283 | 12413228 | 11 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 200 MG, QD | Y | N | 0 | 200 | MG | QD | |||||
| 124132283 | 12413228 | 12 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 100 MG, QD | Y | N | 0 | 100 | MG | QD | |||||
| 124132283 | 12413228 | 13 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | UNK | Y | N | 0 | ||||||||
| 124132283 | 12413228 | 14 | SS | NEBIVOLOL HYDROCHLORIDE | NEBIVOLOL HYDROCHLORIDE | 1 | Oral | 2.5 MG, QD | Y | 0 | 2.5 | MG | QD | ||||||
| 124132283 | 12413228 | 15 | SS | CALCIPARINE | HEPARIN CALCIUM | 1 | Subcutaneous | 0.2 ML, BID | Y | N | 0 | .2 | ML | BID | |||||
| 124132283 | 12413228 | 16 | SS | CALCIPARINE | HEPARIN CALCIUM | 1 | Subcutaneous | UNK | Y | N | 0 | ||||||||
| 124132283 | 12413228 | 17 | SS | hydrochlorothiazide (+) irbesartan | HYDROCHLOROTHIAZIDEIRBESARTAN | 1 | Oral | 300/12.5 MG, QD | Y | 0 | QD | ||||||||
| 124132283 | 12413228 | 18 | SS | hydrochlorothiazide (+) irbesartan | HYDROCHLOROTHIAZIDEIRBESARTAN | 1 | Oral | 150/2.5 MG, QD | Y | 0 | QD | ||||||||
| 124132283 | 12413228 | 19 | C | SERESTA | OXAZEPAM | 1 | U | 0 | |||||||||||
| 124132283 | 12413228 | 20 | C | INEXIUM (esomeprazole sodium) | ESOMEPRAZOLE SODIUM | 1 | U | 0 | |||||||||||
| 124132283 | 12413228 | 21 | C | VOLTARENE | DICLOFENAC SODIUM | 1 | U | 0 | |||||||||||
| 124132283 | 12413228 | 22 | C | SIMVASTATIN. | SIMVASTATIN | 1 | U | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124132283 | 12413228 | 1 | Staphylococcal infection |
| 124132283 | 12413228 | 3 | Medical device site joint infection |
| 124132283 | 12413228 | 4 | Product used for unknown indication |
| 124132283 | 12413228 | 5 | Medical device site joint infection |
| 124132283 | 12413228 | 7 | Dyslipidaemia |
| 124132283 | 12413228 | 9 | Depression |
| 124132283 | 12413228 | 11 | Product used for unknown indication |
| 124132283 | 12413228 | 14 | Hypertension |
| 124132283 | 12413228 | 15 | Product used for unknown indication |
| 124132283 | 12413228 | 17 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124132283 | 12413228 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124132283 | 12413228 | Interstitial lung disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124132283 | 12413228 | 1 | 20160329 | 20160402 | 0 | |
| 124132283 | 12413228 | 2 | 20160402 | 20160418 | 0 | |
| 124132283 | 12413228 | 3 | 20160408 | 20160418 | 0 | |
| 124132283 | 12413228 | 4 | 20160411 | 20160418 | 0 | |
| 124132283 | 12413228 | 5 | 20160329 | 20160329 | 0 | |
| 124132283 | 12413228 | 6 | 20160411 | 20160418 | 0 | |
| 124132283 | 12413228 | 7 | 20160326 | 20160418 | 0 | |
| 124132283 | 12413228 | 8 | 2016 | 0 | ||
| 124132283 | 12413228 | 9 | 20160418 | 0 | ||
| 124132283 | 12413228 | 10 | 2016 | 0 | ||
| 124132283 | 12413228 | 11 | 20160326 | 0 | ||
| 124132283 | 12413228 | 12 | 20160326 | 20160418 | 0 | |
| 124132283 | 12413228 | 13 | 2016 | 0 | ||
| 124132283 | 12413228 | 14 | 20160418 | 0 | ||
| 124132283 | 12413228 | 15 | 20160326 | 20160418 | 0 | |
| 124132283 | 12413228 | 16 | 2016 | 0 | ||
| 124132283 | 12413228 | 17 | 20160326 | 0 | ||
| 124132283 | 12413228 | 18 | 20160326 | 20160418 | 0 |